Clinical trial
Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After…
NCT00289796 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00289796 |
|---|---|
| Title | Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine |
| Official title | Assess the Feasibility of an Investigational Vaccination Regimen, Compared to a 3-dose Primary Vaccination With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib Vaccine) Following Hepatitis B Vaccination at Birth. Primary Vaccination is Followed in the 2nd Year of Life by a Booster Dose of… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | DTPa-HBV-IPV/Hib |
| Enrollment | 121 |
| Start date | Jul 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Feb 10, 2006 |
| Last update posted | Feb 8, 2017 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: